Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MannKind Scores Sanofi As A Partner For Afrezza – But At A Price

This article was originally published in The Pink Sheet Daily

Executive Summary

Sanofi appears to be an ideal match to sell MannKind’s inhaled insulin Afrezza, but the terms of the exclusive worldwide licensing agreement for the product reflect its high-risk nature.

You may also be interested in...



INTERVIEW: Novo Downplays Afrezza, Pins Hopes On Oral Pipeline

Novo Nordisk appears not to be worried about any market impact from Afrezza, MannKind’s recently approved inhalable insulin. In an exclusive interview in Copenhagen, the Danish company’s leadership told PharmAsia News that it had taken sufficient steps to maintain its stronghold on the global insulin market.

Afrezza Approval Comes With Post-Marketing Trial On Lung Cancer, CV Risk

FDA’s unusually specific request suggests continued worries about safety of MannKind’s inhalable insulin; large trial (8,000-10,000 type 2 diabetics) has a variety of goals.

Afrezza Launch Waits On Marketing Partner; MannKind Ramps Up Production

Production of insulin powder inhaler cartridges at Connecticut facility will triple to 400 million a year by launch, which firm expects in 2015.

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

PS077544

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel